Related content

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

By Bebb Gwyn   Smith Colum   Rorke Stewart   Boland William   Nicacio Leonardo   Sukhoo Ryan   Brade Anthony  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 837-845

Springer Publishing Company

Access to resources Recommend Favorite

Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer

By          

International Journal of Oncology, Vol. 46, Iss. 4, 2015-01 ,pp. : 1788-1800

Spandidos Publications

Access to resources Recommend Favorite

Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients

By Zhu Wen-Fang   Li Jian   Yu Li-Chao   Wu Yian   Tang Xin-Ping   Hu Yi-Ming   Chen Yong-Chang  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1211-1219

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By Ogura Michinori   Hatake Kiyohiko   Tobinai Kensei   Uchida Toshiki   Suzuki Tatsuya   Terui Yasuhito   Yokoyama Masahiro   Maruyama Dai   Mori Masakazu   Jewell Roxanne C.   Katsura Koichi   Hotta Tomomitsu  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 5, 2013-05 ,pp. : 466-475

Oxford University Press

Access to resources Recommend Favorite

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

By Horti J.   Juhasz E.   Monostori Z.   Maeda K.   Eckhardt S.   Bodrogi I.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 173-180

Springer Publishing Company

Access to resources Recommend Favorite